Last reviewed · How we verify

NCT03966404

EyeBOX Concussion Study and Registry

Completed Last updated 7 September 2023
What this trial tests

trial testing EyeBOX device in Concussion, Brain in 200 participants. Completed in 1 June 2023.

Timeline
5 August 2019
Primary endpoint
1 June 2023
1 June 2023

Quick facts

Lead sponsorOculogica, Inc.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment200
Start date5 August 2019
Primary completion1 June 2023
Estimated completion1 June 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Oculogica, Inc.

Who can join

Eligibility, any sex, with Concussion, Brain or Mild Traumatic Brain Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to further evaluate eye movements as an aid in the diagnosis of concussion / mTBI and the utility of eye movement assessment in the monitoring of symptoms over time after an initial diagnosis of concussion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Concussion, Brain

Currently open trials in the same condition.

Other Oculogica, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03966404.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing